Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors.

doi:10.1128/JVI.73.1.850-854.1999

Back to search

Article

Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors.

Journal of virology - 1 Jan 1999

Dulioust A, Paulous S, Guillemot L, Delavalle A M, Boué F, Clavel F

Abstract excerpt

Human immunodeficiency virus type 1 (HIV-1) variants that have developed protease (PR) inhibitor resistance most often display cross-resistance to several molecules within this class of antiretroviral agents. The clinical benefit of the switch to a second PR inhibitor in the presence of such resi...

Topics

Acquired Immunodeficiency Syndrome
Drug Resistance
HIV Protease
HIV Protease Inhibitors
HIV-1
Humans
Indinavir
Mutation
Saquinavir

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.